SynthesisWiener klinische Wochenschrift2017
Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis.
Synthesis in Wiener klinische Wochenschrift, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Pooled it
- Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Orchestrating movement: the role of Caveolin-1 in migration and metastasis.Molecular cancer · 2025Review
- Crosstalk between heterogeneous cancer-associated fibroblast subpopulations and the immune system in breast cancer: key players and promising therapeutic targets.Journal of experimental & clinical cancer research : CR · 2025Review
- Petiveria alliacea and Caesalpinia spinosa extracts reduce the generation of cancer-associated fibroblasts in a 3D platform representative of the tumor microenvironment.Cancer cell international · 2025Article
- Caveolin-1: an ambiguous entity in breast cancer.Molecular cancer · 2025Review
- Plant extract fromHeliyon · 2023Article
- The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer.Frontiers in oncology · 2023Review
- Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment.OncoTargets and therapy · 2019Review
- Caveolin-1 is dispensable for early lymphoid development, but plays a role in the maintenance of the mature splenic microenvironment.BMC research notes · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been shown that caveolin-1 plays a potential role as a diagnostic and prognostic biomarker in various cancer types. The aim of the present study was to clarify whether caveolin-1 expressed in the breast cancer stroma could be a prognostic factor for breast cancer patients.
methodsWe searched the PubMed, ScienceDirect and Web of Science databases for published literature investigating associations between stromal caveolin-1 expression and survival outcome in breast cancer patients. With respect to survival outcomes, the pooled hazard ratios (HRs) of caveolin-1 and the 95% confidence intervals (CI) were calculated.
resultsOur meta-analysis identified a total of 10 studies involving 2072 cases. Further investigation demonstrated that a lack of caveolin-1 expression in the breast cancer stroma is a hazard for overall survival (OS) (HR = 2.33, 95% CI: 1.57-3.46) and disease-free/progression-free survival (DFS/PFS) (HR = 3.05, 95% CI: 2.26-4.12) in breast cancer patients. Moreover, lack of caveolin-1 expression in the cancer-associated fibroblasts was a significant predictor of DFS/PFS (HR = 2.79, 95% CI: 1.75-4.46).
conclusionOur results indicated that lack of expression of caveolin-1 in the breast cancer stroma is associated with a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.